title: Modafinil in the treatment of excessive daytime sleepiness.
abstract: Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure. Although modafinil improves measures of sleepiness, it does not generally normalize them, and it may be less effective than other stimulants for some narcoleptic patients. We need head-to-head comparisons of modafinil with traditional stimulants in humans to better define its role. We review the current approved and off-label uses of this drug and the evidence behind them.
authors: Section of Sleep Medicine, Cleveland Clinic Foundation, OH 44195, USA. valentr@ccf.org
authors: Roxanne M
authors: RM
authors: Valentino
authors: Nancy
authors: N
authors: Foldvary-Schaefer
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D045422:Continuous Positive Airway Pressure; D006970:Disorders of Excessive Somnolence; D004347:Drug Interactions; D006801:Humans; D000077408:Modafinil; D009103:Multiple Sclerosis / Q000188:drug therapy; D009290:Narcolepsy / Q000188:drug therapy*; D010300:Parkinson Disease / Q000188:drug therapy; D020181:Sleep Apnea, Obstructive / Q000188:drug therapy*
chemical_list: D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D000077408:Modafinil